Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study

被引：0
|
作者：
Tesfaye, Helen [1 ]
Htoo, Phyo Than T. [2 ]
Paik, Julie M. [2 ]
Zakoul, Heidi [2 ]
Schmedt, Niklas [3 ]
Deruaz-Luyet, Anouk [3 ]
Koeneman, Lisette [4 ]
Wexler, Deborah [5 ]
Patorno, Elisabetta [2 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol, Dept Med, Boston, MA USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Lilly Deutschland GmbH, Bad Homburg, Germany
[5] Harvard Med Sch, Massachusetts Gen Hosp, Div Endocrinol, Dept Med,MGH Diabet Ctr, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
59
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [41] Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients
    Jamalizadeh, Mahdieh
    Hasanzad, Mandana
    Sarhangi, Negar
    Sharifi, Farshad
    Nasli-Esfahani, Ensieh
    Larijani, Bagher
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2021, 20 (02) : 1407 - 1413
  • [42] Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
    Nguyen, Elaine
    Coleman, Craig I.
    Nair, Suresh
    Weeda, Erin R.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (02) : 210 - 215
  • [43] Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Zinman, Bernard
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    Fitchett, David
    Kohler, Sven
    Mattheus, Michaela
    Biomath, Dipl
    Woerle, Hans J.
    Broedl, Uli C.
    Johansen, Odd Erik
    Albers, Gregory W.
    Diener, Hans Christoph
    STROKE, 2017, 48 (05) : 1218 - +
  • [44] A longitudinal study of visceral obesity and risk of diabetic retinopathy in Chinese patients with type 2 diabetes
    Li, Yu Ting
    Chen, Jiaheng
    Niu, Zimin
    Hernandez, Jose
    Wang, Harry H. X.
    Huang, Wenyong
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [45] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Inzucchi, Silvio E.
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans Juergen
    Broedl, Uli C.
    Zinman, Bernard
    CIRCULATION, 2015, 132 (23) : 2271 - 2271
  • [46] Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients
    Mahdieh Jamalizadeh
    Mandana Hasanzad
    Negar Sarhangi
    Farshad Sharifi
    Ensieh Nasli-Esfahani
    Bagher Larijani
    Journal of Diabetes & Metabolic Disorders, 2021, 20 : 1407 - 1413
  • [47] Empagliflozin and the risk of heart failure hospitalisation in routine clinical care: An interim analysis from the EMPagliflozin compaRative EffectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Franklin, J.
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Bartels, D. B.
    Gopalakrishnan, C.
    Kulldorff, M.
    Schneeweiss, S.
    DIABETIC MEDICINE, 2019, 36 : 47 - 47
  • [48] Empagliflozin and the risk of heart failure hospitalization, heart failure worsening and hospital readmission in routine clinical care: interim results from the EMPRISE study
    Patorno, E.
    Pawar, A. Ajinkya
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K.
    Vedin, O.
    Gautam, N.
    Schneeweiss, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 287 - 288
  • [49] A parental history of diabetes is associated with a high risk of retinopathy in patients with type 2 diabetes
    Lapeyre, G.
    Cougnard-Gregoire, A.
    Delyfer, M. -N.
    Delcourt, C.
    Hadjadj, S.
    Blanco, L.
    Pupier, E.
    Rougier, M. -B.
    Rajaobelina, K.
    Mohammedi, K.
    Hugo, M.
    Korobelnik, J. F.
    Rigalleau, V.
    DIABETES & METABOLISM, 2017, 43 (06) : 557 - 559
  • [50] The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study
    Chacko, Jithin
    Dhandapani, Shankar
    Jahagiridhar, Vidhya
    Swaminathan, Krishnan
    INDIAN JOURNAL OF PHARMACOLOGY, 2021, 53 (03) : 229 - 233
12345